medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2003; 2 (4)


Cholestasis: human disease and experimental animal models

Rodríguez-Garay EA

Idioma: Ingles.
Referencias bibliográficas: 86
Paginas: 150-158
Archivo PDF: 101.95 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Trauner M. Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations. Yale J Biol Med 1997; 70: 365-378.

  2. Trauner M, Meier PJ, Boyer JL. Molecular regulation of hepatocellular transport systems in cholestasis. J Hepatol 1999; 31: 165-178.

  3. Arrese M, Accatino L. From blood to bile: recent advances in hepatobiliary transport. Ann Hepatol 2002; 1: 64-71.

  4. Lee J, Boyer JL. Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Sem Liv Dis 2000; 20: 373-384.

  5. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003; 83: 633-671.

  6. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69: 223-231.

  7. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Sem Liv Dis 2002; 22: 123-136.

  8. Vavricka SR, Van Montfoort J, Riem Ha H, Meier PJ, Fattinger K. Interaction of rifamycin SV and rifampicin with organic anion uptake system of human liver. Hepatology 2002; 36: 164-172.

  9. Gerk, PM, Vore, M. Regulation of Expression of the Multidrug Resistance-Associated Protein 2 (MRP2) and Its Role in Drug Disposition. J Pharmacol Exp Ther 2002; 302: 407-415

  10. Hitzl M, Klein K, Zanger UM, Fritz P, Nussler AK, Neuhaus P, Fromm MF. Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human. J Pharmacol Exp Ther 2003; 304: 524-530.

  11. Lee WM. Drug-Induced Hepatotoxicity N Engl J Med 1995; 333: 1118-1127

  12. Strautnieks SS, Bull L, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998; 20: 233-238.

  13. Lykavieris P, Van Mil S, Cresteil D, Fabre M, Hadchouel M, Klomp L, Bernard O, et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol 2003; 39: 447-452.

  14. De Vree JML, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze J-F, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis (abstract). Proc Natl Acad Sci USA 1998; 95: 282-287.

  15. Reyes H, Simon FR. Intrahepatic cholestasis of pregnancy: an estrogen-related disease. Semin Liv Dis 1993; 13: 289-301.

  16. Jansen PL, Muller M. Genetic cholestasis: lessons from the molecular physiology of bile formation. Can J Gastroenterol 2000; 14: 233-238.

  17. Bolder U, Ton-Nu H-T, Schteingart CD, Frick E, Hofmann AL. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology 1997; 112: 214-225.

  18. Gaddipati K, Yang P. Hepatobiliary complications of parenteral nutrition. Gastroenterologist 1996; 4: 98-106.

  19. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991; 13: 267-276.

  20. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, Ter Borg F, Scheper RJ, Tytgat GN, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997; 25: 1539-1542.

  21. Medina JF, Martinez-Anso E, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997; 25: 12-17.

  22. Kullak-Ublick GA, Beuers U, Fahney C, Hagenbuch B, Meier PJ, Paumgartner G. Identification and functional characterization of the promoter region of the human organic anion transporting polypeptide gene. Hepatology 1997; 26: 991-997.

  23. Roelofsen H, Schoemaker B, Bakker C, Ottenhoff, R, Jansen PLM, Oude Elferink RPJ. Impaired hepatocanalicular organic anion transport in endotoxemic rats. Am J Physiol 1995; 269: G427-G434.

  24. Whiting JF, Green RM, Rosenbluth AB, Gollan, JL. Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology 1995; 22: 1273-1278.

  25. Moseley RH, Wang W, Takeda H, Lown K, Shick L, Ananthanarayanan M, Suchy FJ. Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. Am J Physiol 1996; 271: G137-G146.

  26. Green RM, Beier D, Gollan JL. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 1996; 111: 193-198.

  27. Moseley RH. Sepsis-associated cholestasis. Gastroenterology 1997; 112: 302-306.

  28. Trauner M, Arrese M, Lee H, Boyer JL, Karpen S. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J Clin Invest 1998; 101: 2092-2100.

  29. Vos TA, Guido J, Hooiveld EJ, Koning H, Childs S, Meijer DKF, Moshage H, et al. Up-regulation of the multidrug resistance genes, MRP1 and MDR1b, and down-regulation of the organic anion transporter, mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 1998; 28: 1637-1644.

  30. Forker EL. The effect of estrogen on bile formation in the rat. J Clin Invest 1969; 48: 654-663.

  31. Gumucio J, Valdivieso V. Studies on the mechanisms of ethinyl estradiol impairment of bile flow and bile salt excretion in the rat. Gastroenterology 1971; 61: 339-344.

  32. Trams EG, Symeonidis A. Morphologic and functiomal changes in the livers of rats after ligation or excition of the common bile duct. Amer J Pathol 1957; 33: 13-25.

  33. De Vos R, Desmet VJ. Morphological changes of the junctional complex of the hepatocytes in rat liver after bile duct ligation. Br J Exper Pathol 1978; 59: 220-227.

  34. Zimmerman H, Hugi A, Reichen J. The effect of increasing biliary stenosis on hepatic structure in the rat. Hepatology (abstract) 1994; 19: 144.

  35. Rodriguez-Garay EA, Agüero RM, Pisani G, Thrbojevich RA, Farroni, A, Viglianco RA. Rat model of mild stenosis of the common bile duct. Res Exp Med 1996; 196: 105-116.

  36. Orth T, Neurath M, Schirmacher P, Galle PR, Mayet W-J. A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct. J Hepatol 2000; 33: 862-872.

  37. Adler RD, Wannagat F-J, Ockner RK. Bile secretion in selective biliary obstruction. Adaptation of taurocholate transport maximum to increased secretory load in the rat. Gastroenterology 1977; 73: 129-136.

  38. Cooper AD, Jones AL, Koldinger RE, Ockner RK. Selective biliary obstruction. A model for the study of lipid metabolism in cholestasis. Gastroenterology 1974; 66: 574-585.

  39. Boyer JL. Isolated hepatocyte couplets and bile duct units-novel preparations for the study of bile secretory function. Cell Biol Toxicol 1997; 13: 289-300.

  40. Milkiewicz P, Roma MG, Elias E, Coleman R. Pathobiology and experimental therapeutics in hepatocellular cholestasis: lessons from the hepatocyte couplet model. Clin Sci 2002; 102: 603-614.

  41. McGill J M, Yen M S, Cummings O W, Alpini G, LeSage G, Pollok K E, Miller B, et al. Interleukin-5 inhibition of biliary cell chloride currents and bile flow. Am J Physiol 2001; 280: G738-G745.

  42. Trauner M, Nathanson MH, Rydberg SA, Koeppel TA, Gartung C, Sessa WC, Boyer JL. Endotoxin impairs biliary glutathione- and HCO3-excretion and blocks the choleretic effect of nitric oxide in rat liver. Hepatology 1997; 25: 1184-1191.

  43. Denson LA, Auld KL, Schiek DE, McClure MH, Mangelsdorf DJ, Karpen SJ. Interleukin-1b suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J Biol Chem 2000; 275: 8835-8843.

  44. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-1365.

  45. Kullak-Ublick GA. Regulation of organic anion and drug transporters of the sinusoidal membrane. J Hepatol 1999; 31: 563-573.

  46. Arrese M, Ananthanarayanan M, Suchy FJ. Hepatobiliary transport: molecular mechanisms of development and cholestasis. Pediatr Res 1998; 44: 141-147.

  47. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF. The rat canalicular conjugate export pump (mrp2) is down-regulated in intrahepatic and extrahepatic cholestasis. Gastroenterology 1997; 113: 255-264.

  48. Kubitz R, Wettstein M, Warskulat U, Häussinger D. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 1999; 116; 401-410.

  49. Green RM, Hoda F, Ward KL. Molecular cloning and characterization of the murine bile salt export pump. Gene 2000; 241: 117-123.

  50. Simon FR, Fortune J, Iwahashi M, Gartung C, Wolkoff A, Sutherland E. Ethinyl estradiol cholestasis involves alterations in expression of liver sinusoidal transporters. Am J Physiol 1996; 271: G1043-G1052.

  51. Bossard R, Stieger B, O’Neill B, Fricker G, Meier PJ. Ethynilestradiol treatment induces multiple canalicular membrane transport alterations in rat liver. J Clin Invest 1993; 91: 2714-2720.

  52. Arrese M, Pizarro M, Solis N, Koenig C, Accatino L. Enhanced biliary excretion of canalicular membrane enzymes in ethinylestradiol-induced cholestasis. Effect of ursodeoxycholic acid administration. Biochem Pharmacol 1995; 50: 1223-1232

  53. Hornstein B, Stammler L, Bianchi L, Landmann L. Ethinylestradiol increases volume and decreased sinusoidal membrane surface in the rat liver: a stereological analysis. Hepatology 1992; 16: 217-223.

  54. Alvaro D, Gigliozzi A, Piat C, Carli L, Fraioli F, Romeo R, Francia C, et al. Inhibition of biliary bicarbonate secretion in ethinyl estradiol-induced cholestasis is not asociated with impaired activity of the Cl-/CO3- exchanger in rat. J Hepatol 1997; 26: 146-157.

  55. Gartung C, Ananthanarayanan M, Rahman MA, Schuele S, Nundy S, Soroka C, Stolz A, et al. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 1996; 110: 199-209.

  56. Takikawa H, Takamori Y, Sano N, Kuyama Y, Yamanaka M. Changes in biliary excretory mechanisms in rats with ethinyl estradiol-induced cholestasis. J Gastroenterol Hepatol 1998; 13: 186-191.

  57. Meyers M, Slikker W, Vore M. Characterization of cholestasis induced by estradiol-17beta-D-glucuronide in the rat. J Pharmacol Exper Ther 1980; 214: 87-93.

  58. Mottino, AD, Cao J, Veggi LM, Crocenzi F, Roma MG, Vore M. Altered localization and activity of canalicular mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis. Hepatology 2002; 35: 1409-1419.

  59. De Vos R, Desmet V. Morphology of liver cell tight junctions in ethinyl estradiol induced cholestasis. Pathol Res Pract 1981; 171: 381-388.

  60. Elias E, Iqbal S, Knutton S, Hickey A, Coleman R. Increased tight junction permeability: a possible mechanism of oestrogen cholestasis. Eur J Clin Invest 1983; 13: 383-390.

  61. Kan KS, Monte MJ, Parslow RA, Coleman R. Oestradiol 17beta-glucuronide increases tight-junctional permeability in rat liver. Biochem J 1989; 261: 297-300.

  62. Rahner C, Stieger B, Landmann L. Structure-function correlation of tight junctional impairment after intrahepatic and extrahepatic cholestasis in rat liver. Gastroenterology 1996; 110: 1564-1578.

  63. Baumgartner U, Schölmerich J, Weitzel C, Ihling C, Sellinger M, Löhle E, Ruf G, et al. Pattern of bile acid regurgitation and metabolism during perfusion of the bile duct obstructed rat liver. J Hepatol 1995; 22: 208-218.

  64. Stieger B, Landmann L. Effects of cholestasis on membrane flow and surface polarity in hepatocytes. J Hepatol 1996; 24 (Suppl. 1): 128-134.

  65. Roma MG, Luquita MG, Rodriguez-Garay EA. Early changes in bile secretion following relief of short-term biliary obstruction in the rat. Medicina (Buenos Aires) 1988; 48: 381-388.

  66. Boyer JL. Tight junctions in normal and cholestatic liver; does the paracellular pathway have functional significance? Hepatology 1983; 3: 614-617.

  67. Desmet V, Roskams T, Van Eyken P. Ductular reaction in the liver. Path Res Pract 1995; 191: 513-524.

  68. Burt AD, MacSween RNM. Bile duct proliferation-its true significance? Histopathology 1993; 23: 599-602.

  69. Alpini G, Glaser S, Ueno Y, Pham L, Podila P, Caligiuri A, LeSage G, et al. Heterogeneity of the proliferative capacity of rat cholangiocytes following bile duct ligation. Am J Physiol 1998; 274: G767-G775.

  70. LeSage G, Alvaro D, Benedetti A, Glaser S, Marucci L, Baiocchi L, Eisel W, et al. Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats. Gastroenterology 1999; 117: 191-199.

  71. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H, et al. Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. Am J Physiol 2002; 282: G184-G191.

  72. Rodriguez-Garay EA, Larocca C, Pisani G, Alvarez MJ, Rodriguez GP. Adaptive hepatic changes in mild stenosis of the common bile duct in the rat. Res Exp Med 1999; 198: 307-323.

  73. Kono Y, Fukunaga M, Shiraki K, Akiyoshi H. Effects of colestatic agents on the structure and function of bile canaliculi in neonatal rat hepatocytes in primary culture. Tohoku J Exper Med 1997; 181: 9-18.

  74. Stieger B, Fattinger K, Madon J, Kullac-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000; 18: 422-430.

  75. Rodriguez-Garay EA, Spetale MR. Depuración hepática y excreción biliar de rifamicina SV y bromosulfaleína en la rata. Acta Gastroenterol Lat Amer 1969; 1: 133-139.

  76. Kroker R, Anwer MS, Hegner D. The interaction of rifamycin SV with hepatic transport of taurocholic acid in the isolated perfused rat liver. Naun Sch Arch Pharmacol 1978; 302: 323-327.

  77. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptide, Oatp1 and Oatp2. Hepatology 2000; 32: 82-86.

  78. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001; 59: 627-635.

  79. Chisholm J W, Nation P, Dolphin P J, Agellon L B. High plasma cholesterol in drug-induced cholestasis is associated with enhanced hepatic cholesterol synthesis. Am J Physiol 1999; 276: G1165-G1173.

  80. Carpenter-Deyo L, Marchand DH, Jean PA, Roth RA, Reed DJ. Involvement of glutathione in 1-naphthylisothiocyanate (ANIT) metabolism and toxicity to isolated hepatocytes. Biochem Pharmacol 1991; 42: 2171-2180

  81. Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, et al. Characterization of inducible nature of Mrp3 in rat liver. Am J Physiol 2000; 278: G438-G446.

  82. Priestly BG, Cole MG, Plaa GL. Biochemical and morphological parameters of taurolithocholate induced cholestasis. Can J Physiol Pharmacol 1971; 49: 1078-1091.

  83. Layden TJ, Boyer JL. Taurolithocholate-induced cholestasis: taurocholate, but not dehydrocholate, reverses cholestais and bile canalicular membrane injury. Gastroenterology 1977; 73: 120-128.

  84. Roma MG, Peñalva GL, Agüero RM, Rodriguez-Garay EA. Hepatic transport of organic anions in taurolithocholate-induced cholestasis in rats. J Hepatol 1994; 20: 603-610.

  85. Suzuki H, Ito K, Hirohashi T, Kume K, Shimizu T, Sugiyama Y. Molecular cloning of canalicular multispecific organic anion transporter from SD rat liver: mechanism for the impaired expression in Eisai hyperbilirrubinemic rats (Abstract). Hepatology 1996; 24: 131A.

  86. Kostrubsky VE, Vore M, Kindt E, Burliegh J, Rogers K, Peter G, Altrogge D, et al. The Effect of Troglitazone Biliary Excretion on Metabolite Distribution and Cholestasis in Transporter-Deficient Rats. Drug Metab Dispos 2001; 29: 1561-1566.




2020     |     www.medigraphic.com